|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 403/14 | (2006.01) |
| C07D 403/14 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/506 | (2006.01) |
| (11) | Number of the document | 3630751 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18734945.1 |
| Date of filing the European patent application | 2018-05-30 | |
| (97) | Date of publication of the European application | 2020-04-08 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2018/053839 |
| Date | 2018-05-30 |
| (87) | Number | WO 2018/220546 |
| Date | 2018-12-06 |
| (30) | Number | Date | Country code |
| PCT/CN2017/086624 | 2017-05-31 | WO |
| (72) |
CUI, Kai , CN
KONG, Weiyong , CN
CASTRO-PALOMINO LARIA, Julio Cesar , ES
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
Palobiofarma, S.L. , Avenida Ernst Luch 32 TCM3-0401, 08302 Mataro (Barcelona), ES |
| (54) | CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS |
| CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS |